Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study.

ABSTRACT:

Objective

To assess the association between the use of sodium glucose cotransporter 2 (SGLT2) inhibitors and seven serious adverse events of current concern.

Design

Register based cohort study.

Setting

Sweden and Denmark from July 2013 to December 2016.

Participants

A propensity score matched cohort of 17 213 new users of SGLT2 inhibitors (dapagliflozin, 61%; empagliflozin, 38%; canagliflozin, 1%) and 17 213 new users of the active comparator, glucagon-like peptide 1 (GLP1) receptor agonists.

Main outcome measures

The primary outcomes were lower limb amputation, bone fracture, diabetic ketoacidosis, acute kidney injury, serious urinary tract infection, venous thromboembolism, and acute pancreatitis, as identified from hospital records. Hazard ratios and

SUBMITTER: Ueda P 

PROVIDER: S-EPMC6233755 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature